Bliss GVS Pharma Limited
All news and filings related to Bliss GVS Pharma Limited.
View all news & filings- Low impact
Bliss GVS Pharma: Trading Window Closes Oct 1 for Q2 FY27 Results
Bliss GVS Pharma will close its trading window from October 1, 2026. This is in compliance with SEBI regulations and the company's code of conduct. The window will reopen 48 hours after the announcement of the Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Read the summary - Medium impact
Bliss GVS Pharma: Promoter Group Reclassified to Public Category Post Transaction
Bliss GVS Pharma's board noted the completion of a transaction on September 28, 2026, leading to the re-classification of its promoter group to the public category. This follows the acquisition of control by Anupam Rasayan India Limited/PAC after an open offer. Key promoters like Narsimha Shibroor Kamath transitioned from 30.51% to 0% shareholding.
Read the summary - High impact
Bliss GVS Pharma: New Promoters & Directors Appointed, MD Resigns Post Acquisition
Anupam Rasayan India Ltd. and Mates Visa Consultancy Pvt. Ltd. acquired 47.95% stake in Bliss GVS Pharma on September 28, 2026, becoming new promoters. The company appointed three new directors: Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat. Managing Director Narsimha Shibroor Kamath resigned.
Read the summary - High impact
Bliss GVS Pharma: Anupam Rasayan group acquires control; 3 new directors appointed
Anupam Rasayan India Limited, through PAC, acquired 47.95% stake in Bliss GVS Pharma Limited on September 28, 2026, becoming the new promoter. Three new directors, Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat, were appointed. Managing Director Narsimha Shibroor Kamath resigned.
Read the summary - Medium impact
Bliss GVS Pharma Announces Voting Results for Director Appointment
Bliss GVS Pharma Limited announced voting results for appointing Mr. Santosh Parab as Non-Executive and Non-Independent Director. The e-voting period concluded on September 19, 2026. Out of 6,23,23,227 votes polled, 97.04% were in favor of the appointment.
Read the summary - Low impact
Bliss GVS Pharma Open Offer: Post-Offer Advertisement Published, Closure on Aug 10, 2026
Bliss GVS Pharma Limited's open offer, managed by SBI Capital Markets, concluded with the acquisition of 1,669 shares. The offer, for up to 2,77,26,848 shares (26% stake), opened on July 28, 2026, and closed on August 10, 2026. Post-offer advertisement published on September 1, 2026.
Read the summary - Low impact
Bliss GVS Pharma Publishes Newspaper Ad for Share Transfer Extension
Bliss GVS Pharma Limited published newspaper ads on August 25, 2026, announcing an extended special window for re-lodging transfer requests of physical shares. The publication was in compliance with SEBI regulations.
Read the summary - Low impact
Bliss GVS Pharma Submits Newspaper Publication of Postal Ballot Notice
Bliss GVS Pharma Limited has published newspaper advertisements for its Postal Ballot Notice on August 21, 2026. The filings were made in compliance with SEBI regulations.
Read the summary - Medium impact
Bliss GVS Pharma Seeks Shareholder Approval for Director Appointment via Postal Ballot
Bliss GVS Pharma is conducting a postal ballot for shareholders to approve the appointment of Mr. Santosh Parab as a Non-Executive, Non-Independent Director. Remote e-voting is open from August 21, 2026, to September 19, 2026. Results will be announced by September 22, 2026.
Read the summary - Low impact
Bliss GVS Pharma Publishes Unaudited Financial Results for Q1 FY27
Bliss GVS Pharma Limited has published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were advertised in leading English and regional dailies on August 14, 2026, with access to full details via QR code and weblink.
Read the summary - Low impact
Bliss GVS Pharma Grants 3.2 Lakh Stock Options Under ESOP 2019
Bliss GVS Pharma Limited has granted 3,20,000 stock options under its ESOP 2019 plan to employees. The exercise price is ₹43 per option, based on the August 11, 2026 closing price with a 91.32% discount. Vesting occurs in four installments over 48 months.
Read the summary - Medium impact
Bliss GVS Pharma Q1 FY27 Unaudited Results: Revenue ₹221.58 Cr, Profit ₹38.61 Cr
Bliss GVS Pharma reported Q1 FY27 unaudited results. Standalone revenue was ₹221.58 crore and profit was ₹38.61 crore. Consolidated revenue was ₹256.99 crore and profit was ₹36.99 crore. The board also approved a postal ballot notice for the appointment of Mr. Santosh Parab as Director.
Read the summary - Low impact
Bliss GVS Pharma Allots 31,250 Equity Shares Under ESOP Plan 2019
Bliss GVS Pharma Limited allotted 31,250 equity shares under its ESOP Plan 2019 on August 11, 2026. The allotment increased the company's issued share capital to 10,62,75,222 equity shares. The shares are subject to a six-month lock-in period, expiring on February 10, 2027.
Read the summary - Low impact
Bliss GVS Pharma Announces Resignation of Senior Management Personnel
Mr. Sachin Saboo, General Manager – Regulatory and Clinical and a Senior Management Personnel of Bliss GVS Pharma Limited, has resigned. His resignation is effective from July 24, 2026. The reason cited is to pursue professional aspirations.
Read the summary - Medium impact
Bliss GVS Pharma: Independent Directors Recommend Open Offer by Anupam Rasayan
Bliss GVS Pharma's Independent Directors have recommended an open offer by Anupam Rasayan India Limited. The offer is to acquire up to 2.77 crore shares at ₹299 per share, representing 26% of the expanded share capital. The recommendations were published on July 23, 2026.
Read the summary - Low impact
Bliss GVS Pharma to Transfer Unclaimed Dividends & Shares to IEPF Authority
Bliss GVS Pharma will transfer unclaimed final dividends from FY 2018-19 and corresponding shares to the IEPF Authority after October 27, 2026. Shareholders must claim their shares by this date. The company also urges shareholders to complete KYC and nomination for shares held in physical form.
Read the summary - Medium impact
Bliss GVS Pharma Independent Directors Recommend Open Offer at ₹299
Bliss GVS Pharma's Independent Directors Committee recommended an Open Offer at ₹299 per share for up to 26% stake. The total offer value is ₹829.03 crore. The committee found the offer price fair and reasonable based on SEBI regulations, though market prices on July 17, 2026, were higher.
Read the summary - Low impact
Bliss GVS Pharma Notifies Shareholder of Unclaimed Dividend & Share Transfer to IEPF
Bliss GVS Pharma Limited is transferring unclaimed final dividends from 2018-2019 and corresponding shares to the IEPF Authority. This action complies with SEBI regulations and the Companies Act. The notice was published in newspapers on July 21, 2026.
Read the summary - Medium impact
Bliss GVS Pharma Open Offer: Anupam Rasayan to Acquire 26% Stake at ₹299/Share
Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited, is making an Open Offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited, representing 26.00% of the expanded voting share capital. The offer price is ₹299.00 per share. The offer opens on July 28, 2026, and closes on August 10, 2026.
Read the summary - Low impact
Bliss GVS Pharma: Anupam Rasayan's Open Offer Addendum Filed
Bliss GVS Pharma Limited announced an addendum to Anupam Rasayan India Limited's open offer. Mates Visa Consultancy Private Limited has been added as a person acting in concert. The open offer aims to acquire 2,77,26,848 equity shares, representing 26% of the company's capital.
Read the summary - Low impact
Bliss GVS Pharma Appoints KMPs for Material Event Disclosures
Bliss GVS Pharma Limited has authorized its Managing Director, CEO, CFO, and Company Secretary to handle the disclosure of material events to stock exchanges. This designation is in accordance with SEBI regulations.
Read the summary - Medium impact
Bliss GVS Pharma Appoints Santosh Parab as Additional Director, Rahul Adakmol as CEO
Bliss GVS Pharma Limited's Board approved the appointment of Mr. Santosh Parab as Additional Director (Non-Executive Non-Independent) effective July 03, 2026. Mr. Rahul Adakmol will take over as Chief Executive Officer from July 15, 2026. Mr. Narsimha Shibroor Kamath will continue as Managing Director, stepping down as CEO on July 14, 2026.
Read the summary - Medium impact
Bliss GVS Pharma Appoints Santosh Parab as Director, Rahul Adakmol as CEO
Bliss GVS Pharma appointed Mr. Santosh Parab as Non-Executive Non-Independent Director effective July 03, 2026. Mr. Rahul Adakmol will be the new CEO from July 15, 2026. Mr. Narsimha Shibroor Kamath steps down as CEO on July 14, 2026, continuing as MD.
Read the summary - Low impact
Bliss GVS Pharma: Trading Window Closes July 1 for Q1 FY27 Results
Bliss GVS Pharma Limited's trading window will be closed from July 1, 2026, until 48 hours after the announcement of Q1 FY27 financial results. The exact date for the board meeting to declare these results will be announced later.
Read the summary - Medium impact
Bliss GVS Pharma to Deduct Tax on Dividend Payable in FY 2026-27
Bliss GVS Pharma recommended a final dividend of Re. 1.00 per equity share for FY 2025-26. The dividend is payable post-approval at the 41st AGM on July 15, 2026. Record date is July 08, 2026. Shareholders must comply with TDS regulations as dividend income is taxable. Documents for tax deduction are due by July 08, 2026.
Read the summary - Low impact
Bliss GVS Pharma Announces 41st AGM on July 15, 2026, via VC/OAVM
Bliss GVS Pharma Limited will hold its 41st Annual General Meeting on July 15, 2026, at 11:00 a.m. IST. The meeting will be conducted via Video Conferencing (VC)/Other Audio Visual Means (OAVM). Newspaper notices were published on June 19, 2026.
Read the summary - Low impact
Bliss GVS Pharma Allots 2,67,250 Shares Under ESOP-2019
Bliss GVS Pharma Limited has allotted 2,67,250 equity shares under its ESOP-2019 plan on June 11, 2026. The allotment increases the total issued shares to 10,60,56,222. Shares were issued at Rs. 43/- with a Rs. 42/- premium and are under a six-month lock-in until December 11, 2026.
Read the summary - Medium impact
Bliss GVS Pharma's Manufacturing Facility Receives WHO-GMP Compliance Report
Bliss GVS Pharma's manufacturing facility in Palghar has been confirmed compliant with WHO-GMP standards, according to an Inspection Closure Report from the World Health Organization. This signifies the company's commitment to quality and operational excellence.
Read the summary - Low impact
Bliss GVS Pharma Limited Announces Open Offer for Property Auction
Bliss GVS Pharma Limited is conducting an open offer auction for immovable property on June 18, 2026. The reserve price is ₹38,34,368.12. Financial results for the period ending March 31, 2026, are also provided.
Read the summary - Medium impact
Bliss GVS Pharma: Anupam Rasayan's Open Offer Detailed Public Statement Published
Anupam Rasayan India Limited has published a Detailed Public Statement for its open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited, representing 26.00% of the expanded voting share capital. The offer price is ₹299.00 per share, with a total consideration of up to ₹829.03 crore. This follows an agreement to acquire 43.30% of the company's shares.
Read the summary - Low impact
Bliss GVS Pharma: Independent Director Santosh Parab Completes Final Term on May 25
Mr. Santosh Parab has completed his second and final term as an Independent Director at Bliss GVS Pharma Limited. He ceased to be a director effective May 25, 2026. Mr. Parab was re-appointed on May 26, 2021, for a five-year term.
Read the summary - High impact
Anupam Rasayan to Acquire 43.30% Stake in Bliss GVS Pharma for ₹1,369 Crore
Anupam Rasayan India Limited will acquire 43.30% of Bliss GVS Pharma for ₹1,369.51 crore. The deal involves 4,58,03,024 shares at ₹299 each. This transaction will lead to a change in control and trigger an open offer for 26% of equity.
Read the summary - High impact
Bliss GVS Pharma: Promoter Group Sells 43.30% Stake for ₹1,369 Crore
Bliss GVS Pharma Limited announced that its promoter and public shareholders will sell 43.30% stake to Anupam Rasayan India Limited for ₹1,369.51 crore at ₹299 per share. This transaction triggers a mandatory open offer for up to 26% of equity. The Board noted the Share Purchase Agreement executed on May 23, 2026.
Read the summary - High impact
Anupam Rasayan India to Acquire 26% Stake in Bliss GVS Pharma via Open Offer
Anupam Rasayan India Limited is making an open offer to acquire 26% of Bliss GVS Pharma's shares at ₹299 per share, totaling ₹829.03 crore. This follows a Share Purchase Agreement to acquire an additional 43.30% stake. The acquirer will gain control of Bliss GVS Pharma.
Read the summary - Medium impact
Bliss GVS Pharma Publishes Audited Financial Results for FY26 Q4
Bliss GVS Pharma published audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. For Q4 FY26, standalone revenue was ₹8,695.83 crore and consolidated revenue was ₹9,297.41 crore. Full-year standalone revenue reached ₹35,299.31 crore, and consolidated revenue was ₹37,840.44 crore.
Read the summary - Medium impact
Bliss GVS Pharma Approves FY26 Audited Results, Recommends 100% Dividend
Bliss GVS Pharma's Board approved audited standalone and consolidated financial results for FY26. A final dividend of 100% (₹1 per share) was recommended, subject to shareholder approval. The 41st AGM is scheduled for July 15, 2026. BDO India Services Private Limited was re-appointed as Internal Auditor for FY27.
Read the summary - Medium impact
Bliss GVS Pharma Declares 100% Dividend, Schedules 41st AGM for July 15, 2026
Bliss GVS Pharma announced audited standalone and consolidated financial results for the year ended March 31, 2026. The company recommended a 100% final dividend (₹1 per share). The 41st AGM is scheduled for July 15, 2026. BDO India Services re-appointed as Internal Auditor.
Read the summary - Medium impact
Bliss GVS Pharma Board Approves FY26 Audited Results, Recommends 100% Dividend
Bliss GVS Pharma's Board approved audited standalone and consolidated results for FY26, ending March 31, 2026. A final dividend of 100% (₹1 per share) was recommended. The 41st AGM is scheduled for July 15, 2026. M/s. BDO India Services Private Limited was re-appointed as Internal Auditor.
Read the summary - Low impact
Bliss GVS Pharma Grants 1,80,000 Stock Options Under ESOP 2019
Bliss GVS Pharma Limited granted 1,80,000 stock options under its ESOP 2019. The exercise price is ₹43 per option, determined with an 84.20% discount on the May 11, 2026 closing price. Vesting occurs in four installments over 48 months, with a 6-month exercise window post-vesting and a 6-month lock-in on allotted shares.
Read the summary - Medium impact
Bliss GVS Pharma Approves Audited FY26 Results, Recommends 100% Dividend, Schedules AGM for July 15
Bliss GVS Pharma's Board approved audited standalone and consolidated results for FY26. A final dividend of 100% (₹1 per share) was recommended. The 41st AGM is scheduled for July 15, 2026. M/s. BDO India Services Private Limited re-appointed as Internal Auditor for FY27.
Read the summary - Medium impact
Bliss GVS Pharma Announces Voting Results for Director Appointments
Bliss GVS Pharma Limited has announced the results of a postal ballot concerning two special resolutions for director appointments. Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameschandra Shah were appointed as Non-Executive and Independent Directors for five-year terms. Both resolutions passed with overwhelming support via postal ballot.
Read the summary - Low impact
Bliss GVS Pharma Submits Newspaper Publication of Postal Ballot Notice
Bliss GVS Pharma Limited has published a newspaper advertisement for its Postal Ballot Notice on April 10, 2026. This action complies with SEBI Listing Obligations and Disclosure Requirements.
Read the summary - Medium impact
Bliss GVS Pharma to seek shareholder approval for appointing two Independent Directors
Bliss GVS Pharma is conducting a postal ballot for shareholders to approve the appointment of Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Independent Directors for five-year terms. Voting begins April 10, 2026, and ends May 9, 2026, with results expected by May 12, 2026.
Read the summary - Medium impact
Bliss GVS Pharma receives [ICRA]A-(Stable)/[ICRA]A2+ credit rating for ₹100 Crore facilities
Bliss GVS Pharma Limited has received a credit rating of [ICRA]A-(Stable) for long-term and [ICRA]A2+ for short-term facilities. The total rated amount for fund-based and non-fund-based instruments is ₹100 crore. The ratings were assigned by ICRA Limited on April 08, 2026.
Read the summary - Low impact
Bliss GVS Pharma Publishes Newspaper Ad for Share Transfer Window Extension
Bliss GVS Pharma Limited has published newspaper ads regarding the extension of the special window for re-lodging physical share transfer requests. This is in compliance with SEBI regulations. The ads appeared on April 4, 2026, in leading English and regional dailies, providing contact details for lodgement centers.
Read the summary - Medium impact
Bliss GVS Pharma Appoints Two Independent Directors for 5-Year Term
Bliss GVS Pharma Limited appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Additional Directors (Non-Executive and Independent) for a five-year term from April 03, 2026, to April 02, 2031. Member approval will be sought via postal ballot.
Read the summary - Medium impact
Bliss GVS Pharma Appoints Two New Independent Directors
Bliss GVS Pharma Limited appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Non-Executive Independent Directors. Their terms are for five consecutive years, from April 03, 2026, to April 02, 2031. Member approval will be sought via postal ballot.
Read the summary - Low impact
Bliss GVS Pharma Files Certificate Under SEBI Depositories Regulations for Q4 FY26
Bliss GVS Pharma Limited has filed a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The certificate was provided by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Read the summary - Low impact
Bliss GVS Pharma Announces Re. 0.50 Interim Dividend for FY2025-26, Sets Feb 18 Record Date
Bliss GVS Pharma declared an interim dividend of Re. 0.50 per equity share for FY2025-26. The record date for this dividend is February 18, 2026. Tax will be deducted at source as per Income Tax Act provisions. Shareholders must submit relevant tax documents by February 23, 2026.
Read the summary - Low impact
Bliss GVS Pharma Clarifies Rumors of Potential Acquisition by Anupam Rasayan
Bliss GVS Pharma Limited clarified a news report about a potential acquisition by Anupam Rasayan. The company stated the news is speculative and no decision has been finalized by its promoters. Investors should rely only on official company disclosures.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio